PRL-R3 10 MG

PRL-R3 is Peptiva Research Labs' house designation for a synthetic triple receptor-agonist peptide in the retatrutide research class, engineered to engage three incretin and energy-balance receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. As a multi-agonist of these class B G-protein-coupled receptors, it is studied as a reference tool for probing convergent and divergent signaling across metabolic pathways. In laboratory settings, researchers study PRL-R3 in receptor-binding assays, transfected cell lines, and preclinical metabolic models to characterize receptor selectivity, cyclic-AMP signaling, and downstream gene expression linked to glucose and energy homeostasis. In-vitro work also examines comparative potency across the three receptors and the integration of incretin and glucagon signaling. These investigations are mechanistic and aimed at understanding multi-receptor pharmacology, not any therapeutic, weight-management, or clinical use. Peptiva Research Labs supplies it as a research-grade reference compound, HPLC-verified with a COA available. For Research Use Only, not for human or veterinary use.

Read the research guide: PRL-T2 (Tirzepatide-Class GIP/GLP-1 Dual Agonist): Research Overview →

Loading full product details…